(All amounts are in US dollars)
QUEBEC CITY, July 30, 2013 /CNW Telbec/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that it has
completed its previously announced registered direct offering of
$7.8 million of units comprised of common shares and common share
purchase warrants to certain institutional investors. Net proceeds from
this offering, after deducting placement agent fees and other offering
expenses, total approximately $7 million. All of the securities were
offered pursuant to an effective shelf registration statement. Proceeds
from the transaction will be used to continue to fund the Company's
ongoing drug development activities, primarily for the advancement of
its zoptarelin doxorubicin (AEZS-108) program, secondly for its
macimorelin acetate (AEZS-130) program, as well as for general
corporate purposes and working capital.
Burrill Securities LLC acted as the exclusive placement agent for the
As of July 30, 2013 and after issuing 5.2 million common shares at the closing of this offering, the Company had
approximately 31.2 million common shares issued and outstanding,
without giving effect to or assuming the exercise of any outstanding
A shelf registration statement relating to the common shares and
warrants issued in the offering (and the common shares issuable upon
exercise of the warrants) has been filed with the Securities and
Exchange Commission (the "SEC") and has been declared effective. A
prospectus supplement relating to the offering was filed with the SEC.
Copies of the prospectus supplement and accompanying prospectus may be
obtained directly from Aeterna Zentaris Inc., 1405 du
Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5. This
announcement is neither an offer to sell nor a solicitation of an offer
to buy any of Aeterna Zentaris' common shares or warrants. No offer,
solicitation or sale will be made in any jurisdiction in which such
offer, solicitation or sale is unlawful.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing novel treatments in oncology and endocrinology. The
Company's pipeline encompasses compounds from drug discovery to
regulatory approval. For more information, visit www.aezsinc.com.
This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy data
from any of our Phase 3 trials may not coincide with the data analyses
from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to forward-looking statements.
Investors are cautioned not to rely on these forward-looking
statements. The Company does not undertake to update these
forward-looking statements. We disclaim any obligation to update any
such factors or to publicly announce the result of any revisions to any
of the forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or by applicable law.
SOURCE: Aeterna Zentaris Inc.
For further information:
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406